Artelo Biosciences, Inc. (NASDAQ:ARTL) Short Interest Update

Artelo Biosciences, Inc. (NASDAQ:ARTL) was the target of a large drop in short interest in the month of January. As of January 31st, there was short interest totalling 8,600 shares, a drop of 41.1% from the January 15th total of 14,600 shares. Currently, 0.3% of the company’s stock are short sold. Based on an average daily trading volume, of 35,300 shares, the days-to-cover ratio is presently 0.2 days.

Artelo Biosciences Stock Performance

Shares of Artelo Biosciences stock opened at $1.37 on Thursday. Artelo Biosciences has a one year low of $0.91 and a one year high of $1.75. The company has a market cap of $4.43 million, a PE ratio of -0.48 and a beta of 1.25. The business has a 50-day simple moving average of $1.14 and a 200-day simple moving average of $1.17.

Artelo Biosciences (NASDAQ:ARTL) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.06. On average, sell-side analysts predict that Artelo Biosciences will post -2.62 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the company. LADENBURG THALM/SH SH raised Artelo Biosciences to a “strong-buy” rating in a research report on Wednesday, December 25th. HC Wainwright reissued a “buy” rating and set a $5.00 price objective on shares of Artelo Biosciences in a research report on Monday, December 9th. Finally, D. Boral Capital reissued a “buy” rating and set a $6.00 price objective on shares of Artelo Biosciences in a research report on Tuesday, January 14th.

About Artelo Biosciences

Artelo Biosciences, Inc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders.